Forest Lercanidipine Options Include Reformulation, Confirmatory U.S. Trial

Forest Labs is considering a reformulation of its antihypertensive lercanidipine in an effort to optimize the calcium channel blocker's dosing schedule and address outstanding questions from FDA

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet